Priced for a smaller company: management is quietly telling investors the business has already outgrown what the numbers
The model's full reasoning — Q3 2022 call → NOWe need to determine if the call conveys that outsiders are currently underweighting something the company has already done, and management points to a concrete, already-completed or already-operating piece of the business whose contribution is still largely ahead of reported results. Let's analyze the transcript. Management (Dan Lee and Lewis Fanger) discusses Waukegan and Chamonix construction. They emphasize that Waukegan is about to open, and that this is the last call before it opens. They talk about the progress, the hiring, the slot machines, etc. They also mention that the results currently reported are affected by pre-opening costs, and that the future is in these new properties. Key points: - "this is a very, very big call for us, because it is the last time you'll hear from us without Waukegan open. The next time we talk to you, Waukegan should be open" - Lewis Fanger. - Dan Lee talks about Waukegan's potential, citing nearby casinos' revenues, and says "we'll grow the market." - They discuss the construction progress, hiring, etc. - They mention that pre-opening costs are a drag on net income but are an investment. - They also discuss Chamonix progress, and that it's aiming for mid-2023. - They talk about the current quarter's results being affected by various items (insurance, competition, etc.) but overall "okay quarter." Do they convey that outsiders are underweighting something already done? They don't explicitly say "the market is underweighting" but they do say that the next call will be after Waukegan opens, implying that the current results don't reflect Waukegan. They also say that the pre-opening costs are a drag on current net income but are an investment for future net income. That suggests that the reported results understate the company's potential because they don't include the future contribution of Waukegan and Chamonix. But is that a "recognition gap management itself raises"? They are pointing out that the current results are depressed by pre-opening costs, and that the future is bright. However, they don't explicitly say that the market is mispricing or underweighting. They do say "we're spending so much time getting these two new places open, because they really are the future of the company." That implies that the current results don't reflect the future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
PRPH · Q1 2023 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES The transcript shows management explicitly framing the current market view as mismatched with the company's actual position: "Anybody that's focused on us for earnings, you invested or are following the wrong company," "we're not an earnings story this year," and "focus less on revenues and earnings. This is a transition year." They repeatedly contrast this with the multi-billion-dollar assets already built and operating, whose contributions are still ramping or largely ahead. Concrete already-real items with meaningful payoff still ahead include: - The manufacturing facility (already at capacity, running nearly 100% YoY growth, with $25M revenue target for 2024 constrained only by capacity expansion this year; estimated $70M valuation next year plus $40M working capital and tens of millions in equipment). - Nebula Genomics (already generating >100% YoY revenue growth via direct-to-consumer sales; in-house whole-genome processing and B2B ramp expected in H2 202 3, particularly Q4, after validations complete in a couple of months).
KEY · Q3 2022 → YESThe question is: Does management convey that OUTSIDERS ARE CURRENTLY UNDERWEIGHTING SOMETHING THE COMPANY HAS ALREADY DONE — and does management answer that gap by pointing to at least one CONCRETE, A...YES Management repeatedly frames its interest-rate-risk positioning as something that “sets Key apart” and creates “unique and significant upside” that is not yet reflected in the market’s view of the company. Chris Gorman states that the $1.2 billion annualized benefit from re-pricing existing short-term Treasuries and swaps “ even in the event that rates remain at current levels” will arrive over the next two years, and Don Kimble confirms the same mechanics and timing. The $9 billion in short-term Treasuries and $26 billion in swaps are already on the balance sheet; the contribution is simply not yet in the reported results.
KIM · Q2 2018 → YESThe question is: Does management convey that outsiders are currently underweighting something the company has already done, and do they point to at least one concrete, already-completed or already-ope...YES Management explicitly frames the public-private pricing disconnect as a gap in how the company is valued versus its actual assets and execution. They point to the already-completed Toys "R" Us liquidation process (22 boxes resolved into OpCo and PropCo leases, with seven OpCo leases already signed and seven PropCo under 18-24 month resolution) as a concrete, already-real item whose rent contribution is still largely ahead in the reported results, with the 70-80 bps impact on occupancy and same-site NOI expected to be recaptured in Q3 and beyond.